Market News & Trends
Sharp Services Invests $100 Million in US & European Facilities to Increase Capacity & Service Offerings
Sharp Services, a leader in pharmaceutical packaging, clinical trial services & sterile manufacturing has announced a $100 million investment across its global facility network to…
Serán BioScience Expands Commercial Manufacturing With New Campus in Bend, Oregon
Serán BioScience, LLC, a leading science-driven drug development partner, today announced the completion of two of the three new buildings and commencement of construction of…
Orion & Abzena Announce Exclusive Commercial License for Abzena’s Antibody
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced that Orion has obtained an exclusive focused commercial license to one of…
Aenova Expands Sterile Fill & Finish Manufacturing Capacity at its Latina Site
Latina (Italy), 23 October 2025 – Aenova, a leading global contract development and manufacturing organization (CDMO), announces a major investment in its sterile manufacturing capabilities…
Kindeva Announces the Appointment of David Stevens as President
Kindeva, a global contract development and manufacturing organization (CDMO) and drug delivery innovator, announced the promotion of David Stevens, Chief Operating and Commercial Officer, to…
Vertero Unveils New Strategic Direction Focused on Breaking Barriers in Neurodegenerative Diseases
Axial Therapeutics recently announced it has rebranded as Vertero Therapeutics, a biotechnology company breaking barriers in neurodegenerative disease treatment. The new identity reflects the Company's…
Simcha Therapeutics Presents Preclinical Data Demonstrating Potential for Decoy-Resistant IL-18 to Enhance Efficacy of Bi-specific T-cell Engagers
Simcha Therapeutics, a clinical-stage immunobiology company pioneering first-in-class cytokine treatments for cancer, today announced the presentation of preclinical results which demonstrate enhanced efficacy from combining…
Evonik Launches EUDRACAP Colon Functional Capsules in GMP Quality at CPHI Frankfurt
Evonik’s EUDRACAP colon functional capsules are now available produced under good manufacturing practice (GMP). Launched last year, EUDRACAP colon is the first functional, ready-to-fill capsule…
Roquette Returns to SupplySide Global With New, Unified Vision for Health & Nutrition
Roquette, a global leader in plant-based ingredients, will debut its newly expanded portfolio at SupplySide Global 2025. The event marks the company’s first presentation combining…
Hovione Completes Initial $100M Investment Cycle to Expand US Operations at New Jersey Manufacturing Campus
Hovione, a fully-integrated global CDMO, today announced the completion of an initial multi-million-dollar investment cycle to expand its manufacturing campus in East Windsor, New Jersey.…
XOMA Royalty & LAVA Therapeutics Announce Amendment to Purchase Agreement
XOMA Royalty Corporation and LAVA Therapeutics N.V. recently announced that they have reached an agreement to amend their previously announced definitive share purchase agreement .…
New Roquette Pharmaceutical Innovation Center to Strengthen Latin America as Collaborative Hub
New Roquette Pharmaceutical Innovation Center to Strengthen Latin America as Collaborative Hub The Health & Pharma Solutions facility offers state-of-the-art laboratory and training rooms for…
Enterome Receives FDA Fast Track Designation in Follicular Lymphoma for Lead OncoMimics Immunotherapy
Enterome recently announced the US FDA has granted Fast Track designation for follicular lymphoma in the low tumor burden “watch-and-wait” setting for its lead OncoMimics…
Entera Bio to Present New Clinical Data From Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
Entera Bio Ltd. recently announced it will present new clinical data from its Phase 2 trial of EB613 at the upcoming North American Menopause Society…
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
Gyre Therapeutics recently announced its indirect, majority-owned subsidiary, Gyre Pharmaceuticals Co., Ltd. (Gyre Pharmaceuticals), has completed patient enrollment in the 52-week Phase 3 clinical trial…
Amphista Therapeutics Nominates Orally Available Targeted Glue Degrader as its First Clinical Development Candidate
Amphista Therapeutics recently announced the nomination of AMX-883; a potent, selective and orally bioavailable degrader of BRD9, as its first clinical development candidate. Amphista is…
Owen Mumford Launches EcoSafe Safety Syringe Platform - Smarter for Budgets & Kinder to the Planet
The EcoSafe 1ml safety syringe (previously branded UniSafe) is compatible with the new reusable EcoSafe autoinjector – creating the first and only fully integrated safety…
Tagworks Pharmaceuticals Announces CTA Authorization & Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors
Tagworks Pharmaceuticals BV recently announced the Dutch regulatory authorities approved the Clinical Trial Application (CTA) for the CleavHER Phase 0/1 clinical trial, sponsored by the…
Quotient Sciences & Biorasi Partner to Accelerate Early Phase Clinical Trials to Patient Proof-of-Concept
Quotient Sciences recently announced a strategic partnership to deliver fully integrated early phase clinical trial solutions. The partnership will combine Quotient Sciences’ expertise in early clinical…
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
Denali Therapeutics Inc. recently announced the US FDA has extended its review timeline of the Biologics License Application (BLA) seeking accelerated approval of tividenofusp alfa…
